Pharmaceuticals

Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum

Addition increases diversity of Board governance and supports further independent expertise DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing...

2022-09-01 07:30 4129

Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet pat...

2022-08-31 21:00 3505

NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421

TAIPEI, Aug. 31, 2022 /PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of this study is to asses...

2022-08-31 12:24 2510

Biomedical industry bears fruit again in National Nanning Economic & Technological Development Area

NANNING, China, Aug. 31, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by Guangxi Yizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic & Technological Development Area ("Area") has been granted the registration certificate of class ...

2022-08-31 00:32 3095

LifeTech Scientific Corporation (1302.HK) Announces 2022 Interim Results

* Revenue increased by 20.4%, net profit attributable to owners of the  Company increased by 34.4% after excluding certain non-recurring items SHENZHEN, China, Aug. 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally ...

2022-08-30 21:45 5476

'Medlab Asia & Asia Health 2022' to Promote Thailand as a Medical Hub of ASEAN by Collaborating with Department of Health Service Support and Medical Industry

BANGKOK, Aug. 30, 2022 /PRNewswire/ -- 'Medlab Asia & Asia Health 2022' is the leading medical event in the ASEAN region which is all set to run in Thailand for the first time, co-hosted by IMPACT Exhibition Management and Informa Markets, and supported by Department of Health Service Support, Mi...

2022-08-30 15:35 3074

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Data showed an excellent safety profile with no adverse events among the five subjects treated. Company continues to explore doses in the ongoing Phase II dose escalation study GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock ...

2022-08-29 15:59 4133

Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress

* The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently. * Cash reserve was nearly RMB 1.5 billion, which provided support to sustainable innovation and commercialization. * The novel adjuvants vaccine will create a strong growth engine. TAIZHOU, China, ...

2022-08-29 13:08 5038

Fosun International Listed in Forbes 2022 China ESG 50

HONG KONG, Aug. 29, 2022 /PRNewswire/ -- Forbes China recently released its "2022 China ESG 50" list. Fosun International has been included on the list for its outstanding ESG performance and its active contribution to the fight against the COVID-19 pandemic.Forbes China pointed out that ESG is s...

2022-08-29 12:52 4945

Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization

BEIJING, Aug. 26, 2022 /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (1477.HK) released its 2022 interim report. The Company's overall performance remained remarkable despite the fact that the pandemic caused considerable trouble in commercializing its ophthalmic prod...

2022-08-26 22:09 13090

Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead™ RNAi delivery platform f...

2022-08-26 21:54 11170

Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference

Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both intravenous and subcutaneous administration Poster presentations demonstrate synergistic effects of s...

2022-08-26 19:30 3595

VISTA Eye Specialists joins Qualitas Health Family to further strengthen Qualitas' healthcare foothold in Asia Pacific

PETALING JAYA, Malaysia, Aug. 26, 2022 /PRNewswire/ -- VISTA Eye Specialists (VISTA) officially joins the Qualitas Health integrated network of clinics in Asia in a collaboration borne out of the attraction towards values that they share - to provide the Malaysians with access to quality healthcar...

2022-08-26 08:00 4752

Everest Medicines Announces the Departure of CEO, Kerry Blanchard

SHANGHAI, Aug. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific m...

2022-08-26 07:30 5586

Innovent Announced 2022 Interim Results and Business Updates

* Leading the Way in Developing a More Sustainable Business Model for Innovative Biopharmaceutical Companies * Commercial Model and Platform Upgraded to Stage 2.0 * A Robust Pipeline of 34 Valuable Assets Supporting Continuously Growth Momentum ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2022...

2022-08-25 20:06 7015

CStone Pharmaceuticals Reports 2022 Interim Results and Business Updates

SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2022 interim financial results an...

2022-08-25 18:00 7047

Everest Medicines Announces Interim Results for First Half of 2022

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, today announced its interim r...

2022-08-24 21:10 7873

Mangosteen Peel as Medicine - CU's Faculty of Veterinary Science is Successful in Replicating Mangosteen Peel Extract, Treatment for Intestinal Inflammation in Humans and Animals

BANGKOK, Thailand, Aug. 24, 2022 /PRNewswire/ -- The Faculty of Veterinary Science,Chulalongkorn University has researched and replicated "Hydroxy- xanthones", the vital extracts rich in antioxidants found in mangosteen peels that kill germs and halt infections in the intestinal mucosa. It hopes t...

2022-08-24 10:00 3009

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ -- The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the ...

2022-08-24 09:00 4276

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2022-08-24 08:00 4699
1 ... 139140141142143144145 ... 184